Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 4/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.45 |
| ▸ | BACE1 | P56817 | 6/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 4/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12310483 | 0.81 | HSD17B1 (0.43) | HSD17B1HSD17B2BACE1S1PR1BACE2 | |
| SCHEMBL17192152 | 0.81 | SNCA (0.47) | HSD17B1HSD17B2BACE1CYP11B1CYP11B2 | |
| SCHEMBL2407001 | 0.80 | LRRK2 (0.53) | BACE1S1PR1BACE2CYP11B1CYP11B2 | |
| SCHEMBL12310278 | 0.80 | HSD17B1 (0.43) | HSD17B1HSD17B2BACE1CYP11B1CYP11B2 | |
| SCHEMBL9965313 | 0.80 | HSD17B1 (0.43) | HSD17B1HSD17B2BACE1S1PR1BACE2 | |
| SCHEMBL14817182 | 0.79 | HSD17B1 (0.54) | HSD17B1HSD17B2CYP11B1CYP11B2PGR | |
| SCHEMBL12128119 | 0.77 | MAPT (0.47) | HSD17B1HSD17B2BACE1PGRCNR2 | |
| SCHEMBL12673461 | 0.77 | HSD17B1 (0.40) | HSD17B1HSD17B2BACE1S1PR1BACE2 | |
| SCHEMBL3954195 | 0.77 | S1PR1 (0.42) | HSD17B1HSD17B2BACE1S1PR1BACE2 | |
| SCHEMBL1872343 | 0.75 | FLT3 (0.41) | HSD17B1HSD17B2BACE1S1PR1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404689-B2 | Heterocyclic amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8202854-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110280867-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2011-11-17 | — | — | US | disclosed |
| US-8012960-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100247519-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| US-7763606-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070099898-A1 | Heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME LLC | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099898-A1 | Heterocyclic aspartyl protease inhibitors | CHRM1, ACHE, CHRM2 | HSD17B1 1173/4885HSD17B2 1671/4885BACE1 4/4885 |
| US-20100247519-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, ACHE, CHRM2 | HSD17B1 1173/4885HSD17B2 1671/4885BACE1 4/4885 |
| US-20110280867-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, ACHE, CHRM2 | HSD17B1 1173/4885HSD17B2 1671/4885BACE1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.